Table 1 –

Summary of adjuvant imatinib trials in primary GIST.

Trial	Phase	Entry Criteria	Treatment Dose/Duration	Relevant Findings
ACOSOG Z900151	III	Tumor ≥ 3cm	400 mg daily for 1 year vs placebo	1-year RFS 98% vs 83% No difference in OS
SSG XVIII52, 53	III	High-risk tumor	400 mg daily for 1 year vs 3 years	3-year RFS 73% vs 55% 3-year OS 92% vs 85% 3-year DSS 95% vs 89%¶
EORTC 6202454	III	Intermediate and high-risk tumor	400 mg daily for 2 years vs no treatment	5-year IFFS 87% vs 84%¶ 3-year RFS 84 vs 66% 5-year RFS 69% vs 63%
PERSIST-555	II	Intermediate or high-risk tumor	400 mg daily for 5 years	5-year RFS 90% 5-year OS 95% 50% in treatment arm discontinued imatinib

^¶These findings were not statistically significant. ACOSOG, American College of Surgeons Oncology Group; EORTC, European Organization for the Research and Treatment of Cancer; SSG, Scandinavian Sarcoma Group; PERSIST-5, Postresection Evaluation of Recurrence-free Survival for Gastrointestinal Stromal Tumors With 5 Years of Adjuvant Imatinib; RFS, Recurrence Free Survival; OS, Overall Survival; IFFS, Imatinib-Failure Free Survival